AstraZeneca PLC Form 6-K: Voting Rights & Compliance Insights (June 2025)

Here are the key pieces of information extracted from the provided section of the financial report for AstraZeneca PLC:

1. Filing Information:

• Type: Form 6-K
• Commission File Number: 001-11960
• Date of Report: June 2, 2025

2. Company Information:

• Company Name: AstraZeneca PLC
• Headquarters: 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.

3. Total Voting Rights:

• Issued Share Capital: 1,550,657,962 ordinary shares of US$0.25.
• Total Number of Voting Rights: 1,550,657,962 (No shares are held in Treasury).

4. Regulatory Compliance:

• This notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1.
• The total number of voting rights may be used by shareholders to determine whether they need to notify their interest in, or changes to their interest in, AstraZeneca PLC.

5. Company Profile:

• AstraZeneca is a global, science-led biopharmaceutical company engaged in the discovery, development, and commercialization of prescription medicines across various therapeutic areas including Oncology, Rare Diseases, and BioPharmaceuticals.

6. Contact Information:

• Company Secretary: Adrian Kemp
• Date Signed: June 2, 2025

This report helps assess AstraZeneca's governance structure, shareholder rights, and transparency in reporting voting rights, which is essential for investors and analysts monitoring corporate governance and compliance.